ADAnita R. Denisova

Anita R. Denisova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anita R. Denisova has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • When to get treatment for coughing: A choice of treatment

    by A. R. Denisova, V. D. Denisova, E. V. Lurie

    Acute respiratory infections remain one of the leading causes of pediatric department visits, which places a substantial financial burden on healthcare system and generates high socioeconomic costs. Cough, one of the most common symptoms of acute respiratory infections in children, is a complex pathophysiological reflex intended to maintain airway clearance and patency by removing secretions and foreign objects. Respiratory tract infections in children often give rise to bronchial hyperresponsiveness characterized by bronchial smooth muscle contraction, edema of the bronchial mucosa, and mucus hypersecretion, which may be a manifestation of broncho-obstructive syndrome. Effective treatment of cough depends largely on the accurate and timely diagnosis of the underlying condition. Cough medicines fall into two main categories: cough suppressants (antitussive agents) and cough clearance promoters (mucoactive agents). This article discusses the physiological aspects of cough occurrence in respiratory diseases, and presents the causes of bronchial hyperresponsiveness as a key factor requiring a sensitive attention to choose treatment strategy. Special attention has been given to the modern approaches to the treatment of cough in children due to acute respiratory infections, including the use of combination mucoactive drugs and herbal medications. These agents have a multi-target effect: they may augment mucociliary clearance, supress cough intensity, reduce inflammation, and alleviate symptoms. The use of such medications helps reduce polypharmacy, mitigate the risk of side effects, enhance medication adherence, and avoid unnecessary antibiotic therapy. These drugs have been shown to be highly effective and safe in children with infectious diseases associated with coughing.

  • Open Access

    Evaluation of the spectrum of sensitization in children with bronchial asthma in Moscow and Moscow region

    by N. G. Kolosova, A. R. Denisova, V. D. Denisova

    Introduction. Chronic allergic respiratory inflammation triggered by contact with cause-significant allergens is the pathogenetic characteristic of atopic bronchial asthma. Identification of sensitization is essential for successful therapy of bronchial asthma.Aim. To study age-related changes in the spectrum of sensitization to allergens in children with bronchial asthma followed up in healthcare facilities of Moscow and Moscow region.Materials and methods. A total of 970 children aged 0 to 17 years 11 months residing in Moscow and Moscow region were include in the retrospective, cross-sectional, population-based study of the spectrum of allergic sensitization of bronchial asthma based on their medical records.Results. Total IgE was only assessed in 37.11% (n = 360) of patients from the study cohort of children with bronchial asthma, of which an elevated IgE level was identified in 81% of cases (292 children), suggesting the prevalence of the atopic bronchial asthma phenotype over non-atopic asthma phenotype. The analysis showed the changing patterns of allergen sensitization by age group. Most of the patients, irrespective of their age, showed sensitization to household allergens. In addition to household allergen sensitization, food sensitization was also reported in 36% in children under 4 years of age, which was the highest rate as compared to other age periods. Sensitization to household and pollen allergens was found to increase significantly as children age (p < 0.05). Cross-sensitization (to pollens produced from wind-pollinated plants) to food allergens was low, but increased from an early age up to 15-18 years. Allergic rhinitis (AR) is a very common comorbidity of asthma and accounts for 18% with a gradual increase in indicators by the age of 18. Children with concurrent asthma have almost the same incidence of developing atopic dermatitis up to age 18.Conclusions. The prevalence of sensitization to food allergens has been established in children with asthma residing in Moscow and Moscow region under 4 years old, and the prevalence of sensitization to household, pollen and epidermal allergens — over 5 years old, which should be taken into account when managing these patients.

  • Open Access

    Diagnostic verification and routing of children with bronchial asthma using the current information system capabilities

    by Anita R. Denisova, Natalia A. Geppe, Aleksandr B. Malahov, Veronika D. Denisova, Nikoloz M. Gaboshvili

    Asthma is a heterogeneous, chronic, and recurrent inflammatory lung disease that also affects children. In recent decades, the incidence of bronchial asthma has been steadily increasing. In 2021, asthma affected 0.89% and 1.87% of Russian children aged 0–14 and 15–17 years, respectively; however, the prevalence of asthma according to official statistics is lower than the real data. Therefore, a significant proportion of patients do not receive proper treatment, which ultimately affects the quality of life of these patients and their parents. Early and accurate diagnosis of bronchial asthma and identification of children with an uncontrolled disease course will provide an opportunity to select/change therapy to achieve remission, thereby preventing possible negative consequences of the disease. In Moscow, according to Order No. 947n of the Ministry of Health of Russia, to improve the quality of medical services, including outpatient care, the Unified Medical Information and Analytical System (UMIAS) has been implemented, which has improved the availability and quality of medical services of public healthcare institutions in the city. This study proposes simple algorithms, and their integration into the UMIAS system will facilitate diagnosis verification for pediatricians and provide allergologists with tools for timely and structured routing of patients with uncontrolled bronchial asthma.


  • Open Access

    Features of Statistical Accounting of Allergic Diseases in Children — Evidence from Moscow

    by Anita R. Denisova, Alexander B. Malahov, Alexandr N. Pampura, Elena A. Vishneva, Margarita A. Soloshenko, Nikoloz M. Gaboshvili, Leyla S. Namazova-Baranova

    Background. The emergence of new functional capabilities of statistical accounting made it possible to conduct a comparative analysis of the morbidity of allergic pathologies according to the registers of allergists and pediatricians from the Unified Medical Information and Analytical System (UMIAS) of Moscow with data from the Form of Federal Statistical Observation No. 12 (FSO No. 12). The aim of the study is to investigate the potential of using UMIAS for assessing/monitoring the morbidity of allergic diseases, including bronchial asthma in children, using the example of several outpatient clinics (OPCs) in Moscow. Methods. A study of combined design has been carried out. The data of children of several OPCs in Moscow were analyzed — data from UMIAS (observation registers of pediatricians and allergist-immunologists) and from the reporting forms of the FSO No. 12. Results. For a comparative analysis of statistical data from UMIAS and FSO No. 12, we studied the information of 60,851 children under 18 years of age. It was revealed that out of 60,851 children: allergic rhinitis according to FSO No. 12 and UMIAS was established in 1001 and 1059 patients; atopic dermatitis — in 142 and 345; urticaria — in 363 and 33; angioedema — in 4 and 16, respectively; food allergy — in 233 children according (to FSO No. 12) and in none of the children (according to UMIAS). Out of 60,851 children, 619 children were diagnosed with bronchial asthma according to the annual report (FSO No. 12) and 537 according to the pediatrician’s observation registers (UMIAS). At the same time, it was found that the diagnosis of bronchial asthma is not available as a separate nosology in the registry of an allergist-immunologist, and information about children with bronchial asthma is available to this specialist only when analyzing the uploaded information about children with other allergic diseases. Conclusion. A adequate sample ensured a high representativeness of the results obtained. The differences in the incidence rates of allergic diseases revealed by a comparative analysis of data from various sources — UMIAS and FSO No. 12 — indicate the need to improve both the system of statistical registration of incidence and the development of modern algorithms for early diagnosis and dynamic monitoring of children with allergies.


  • Open Access

    Symptomatic treatment of cough in children

    by N. A. Geppe, A. R. Denisova, V. D. Denisova, N. G. Kolosova, I. V. Grebeneva

    Cough is one of the most common symptoms in paediatric practice. Cough nature, duration, intensity, frequency, time and cause of occurrence should be considered in the differential diagnosis of its causes. Sputum evacuation disorders and changes in its rheological properties are indications for the prescription of mucoactive drugs. Despite the fact that the drugs included in this group have different mechanisms of action, all of them restore mucociliary clearance and lead to effective evacuation of secretions from the respiratory tract. Herbal medicinal products can be used along with classic mucoactive drugs (mucolytics, mucopegulators and mucokinetics). Ivy leaves are an example of a well-known and meticulously researched source of phytopharmaceutical products, they are included in the ESCOP monograph and entered into the positive list of the German Commission E. The efficacy and safety of ivy leaf products have been demonstrated in various controlled clinical studies. The authors presented a review of published clinical studies and non-interventional studies involving a total of 65,383 patients suffering from both acute and chronic respiratory diseases. The studies demonstrated the efficacy of ivy leaf extract preparations as achievement of a higher level of bronchodilation and surfactant production, which led to bronchospasmolytic, secretolytic, expectorant and, in turn, antitussive action. Herbal medicinal products are now actively used in the treatment of new coronavirus infection. Hedelix is one of the ivy leaf extract pharmaceutical preparations approved for use in children over the age of two years.


  • Open Access

    Algorithms to improve the EMIAS system to optimize the routing of adolescents with atopic dermatitis

    by Anita R. Denisova, Денисова Анита Робертовна

    Atopic dermatitis is a systemic, chronic, relapsing, inflammatory disease affecting mainly the skin. In recent decades, the incidence of atopic dermatitis has been steadily increasing. The burden of atopic dermatitis in adolescents is particularly severe because they are in a transitional and vulnerable growth phase with associated biological, cognitive, social, and emotional transformations. Early and correct diagnosis of atopic dermatitis, as well as the identification of adolescents with an uncontrolled course of the disease, will provide an opportunity to select/change therapy, which can lead to remission, preventing the negative effects of the disease. A number of studies have shown that the negative mental health effects of atopic dermatitis on adolescents include an increased risk for depression, attention deficit hyperactivity disorder, anxiety and behavior disorders, sleep disturbances, and suicidal ideation. EMIAS is a unified medical information and analytical system, which was created to improve the availability and quality of medical services provided by Moscow public health institutions. The introduction of EMIAS has led to improvements in the healthcare system. The article proposes validated and simple tools, the integration of which into the EMIAS system, will facilitate the verification of diagnosis and personalized (based on recommendations at the population level) management of adolescents with atopic dermatitis in the outpatient phase by pediatrician and allergist.


  • PATHOGENICITY ANALYSIS OF THE NEW MISSENSE MUTATION IN THE MYOF GENE DETECTED IN A FEMALE PATIENT WITH HEREDITARY ANGIOEDEMA WITH NORMAL LEVEL OF C1-INHIBITOR

    by N.A. Pechnikova, Yu.V. Ostankova, M.A. Saitgalina, A.M. Bebyakov, A.R. Denisova, A.A. Totolian

    Hereditary angioedema (HAE) is a genetically determined disorder accompanied by specific symptoms associated with sporadic subcutaneous and submucosal edema. The described cases of type III HAE not associated with mutations in the SERPING1 gene are characterized by the corresponding clinical picture with normal values and functional activity of the C1-inhibitor. Type III HAE is associated with mutations in the F12, PLG, ANGPT1, KNG1, MYOF, and HS3ST6 genes. Mutations in the MYOF and HS3ST6 genes remain the least studied as yet. And as for the MYOF gene, a single mutation, Arg217Ser, is known to be associated with the development of HAE. The purposes of this research were to study the new missense mutation NC_000010.10:g.95093020C>T in the MYOF gene and predictive assessment of its contribution to the HAE pathogenesis using the bioinformatics analysis. There was a blood sample obtained from a 14 y/o female patient with HAE clinical manifestations and without a decrease in the level and the lack in function of the C1-inhibitor. The research methods included sequencing of the patient's complete exome, bioinformatic analysis of the MYOF gene mutation using a number of databases and Internet resources with the purpose of assessing the conservation of the amino acid position of the substitution and predicting the effect of the mutation on the protein. Results: the girl had a previously undescribed missense mutation NC_000010.10:g.95093020C>T in exon 42 of the MYOF gene (isoform A) in the heterozygous state. The mutation resulted in the replacement of arginine with glutamine at position 1590 of the amino acid sequence (p.Arg1590Gln, rs201619869). The use of bioinformatics analysis allowed assuming the potential pathogenicity of the detected missense mutation, which could cause the observed edema. The possible pathways for the involvement of myoferlin with the detected mutation in the HAE pathogenesis are discussed in the Article. The use of in silico analysis allowed conducting the detailed study of the detected mutation considering its effect on the protein structure, which is the basis of its normal functioning. According to the results of the study, rare mutations in the MYOF gene can be involved in the HAE pathogenesis provoking edema through various cascades of biochemical reactions. In the course of the study, a new missense mutation in the MYOF gene, pathogenetically significant for the HAE development, was described for the first time.


  • Open Access

    Applying bioinformatic analysis for prognostic assessment of the HS3ST6 missense mutations clinical significance in the development of hereditary angioedema

    by N. A. Pechnikova, Yu. V. Ostankova, M. A. Saitgalina, A. M. Bebyakov, A. R. Denisova, N. S. Podchernyaeva, A. A. Totolian

    Hereditary angioedema (HAE) is a genetically determined disease characterized by recurrent attacks of edema affecting the subcutaneous and/or submucosal layers of tissue, face, lips, neck, extremities of the body, oral cavity, intestine and/or larynx. In the latter case, the disease becomes life-threatening. The majority of HAE cases are associated with decreased levels of C1 (C1-esterase inhibitor), there are also descriptions of HAE with dysfunctional C1 inhibitor and HAE with normal C1 inhibitor. In the first and second variants, mutations in the C1NH gene are the cause of the disease. HAE with normal quantitative and functional levels of C1-inhibitor has the same clinical manifestations but with mutations in other genes, including F12, PLG, ANGPT1, KNG1, MYOF, and HS3ST6. Currently, mutations in the HS3ST6 gene remain poorly understood; only one missense mutation (p.Thr144Ser, rs746467957) associated with the development of HAE has been described.The aim of our work was to study new mutations in the HS3ST6 gene and analyze in silico their prognostic nature and clinical significance for the development of hereditary angioedema.The material was whole blood samples obtained from 13 patients with symptoms of hereditary angioedema without reduced levels and function of C1-INH.Whole exome sequencing of patients, bioinformatic analysis of HS3ST6 gene mutations using a number of databases and Web resources to predict the effect of mutations on the protein and assess the conservatism of the positions of the mutations detected was involved in study methods.Mutations in the HS3ST6 gene were identified in four patients, including two cases with two mutations simultaneously. Application of bioinformatic analysis allowed us to obtain new data on four missense mutations in the studied gene. Potential pathogenetic significance was determined for three of them. The mutation NC_000016.9:g.1962132G>A (p.A163V) is most likely to be involved in pathogenesis of HAE by indirect disruption of heparan sulfate O-sulfation directly within the protein. The NC_000016.9:g.1962024G>A mutation (p.P199L) appears to lead to the development of the disease through disruption of docking with SDC2 heparan sulfate. In the NC_000016.9:g.1962046C>T (p.A192T) mutation, destabilization of the 192 amino acid position next to PAPS, may contribute to disruption of heparan sulfate O-sulfation through disruption of protein functional activity and, therefore, catalysis transfer of sulfo group to heparan sulfate syndecan-2. Thus, in all three cases, the formation of HAE appears to be possible due to disruption of the O-sulfation steps of heparan sulfate syndecan-2.Considering that in silico methods offer new opportunities to assess the pathogenetic significance of mutations, the application of bioinformatic analysis can contribute to a detailed investigation of the causes of hereditary angioedema. The present work convincingly demonstrates that rare mutations in the HS3ST6 gene may be involved in the pathogenesis of HAE and provoke edema due to increased bradykinin release.


  • Open Access

    The role of herbal medicines in treating cough in children

    by N. G. Kolosova, V. D. Denisova, A. R. Denisova, I. V. Grebeneva, A. Yu. Sedova

    The physiological role of cough is to restore mucociliary clearance in the respiratory tract. However, if there are inflammatory changes against the background of a respiratory infection, cough may be non-productive and impair the patient’s quality of life. For a rational choice of drug, the true cause of cough should be determined on the basis of history, physical examination and, if necessary, additional instrumental/laboratory investigations. Modern phytopharmaceuticals are considered effective and safe for cough relief. Herbal medicines contain biologically active substances, which are incorporated into the metabolic processes of the body in a more natural way, in contrast to synthetic analogues. The article focuses on the effectiveness of an ivy leaf extract, which has a complex composition: it contains saponins, flavonoids, glycosides, as well as components of essential oils. Due to its composition, it has several effects: expectorant due to its secretolytic and mucolytic action, and antispasmodic based on the increased sensitivity of β2-adrenoreceptor cells of bronchial smooth muscle cells to endogenous and exogenous stimulation, on reducing intracellular calcium levels and bronchial relaxation. The efficacy of ivy leaf extract has been shown in a total of more than 20 clinical trials, mainly in children suffering from upper respiratory tract infections. Cough treatment aims at changing the rheological properties of the secretion and increasing the effectiveness of the cough. The good compatibility of herbal medicines with other drugs, including antibiotics, allows their use not only as monotherapeutic agents, but also in combination therapy for the treatment of cough in children.


  • Open Access

    Application of hypertonic saline in children with acute bronchitis

    by A. R. Denisova, N. G. Kolosova, I. V. Grebeneva, V. D. Denisova, M. V. Glukhova, E. V. Lurie

    Introduction. Cough is the most common manifestation of respiratory infections of the upper and lower respiratory tract and indicates impaired mucociliary clearance. The cause of cough must be determined to choose the management tactics for children with cough. The most commonly used mucoactive drugs liquefy sputum as a result of a direct action of the components on the tracheobronchial secretion and/or mucosa of the respiratory tract. Given the mucoactive effect of hypertonic salines, we conducted an open clinical study of the effectiveness of 3% hypertonic saline with hyaluronic acid in acute bronchitis in children.Aim of the study. To evaluate the clinical effect of 3% hypertonic saline with hyaluronic acid in acute bronchitis in children.Materials and methods. Clinical efficacy and safety of 3% hypertonic saline with hyaluronic acid in 50 patients aged 3 to 12 years old with acute bronchitis were evaluated in the dynamics on the 1st, 3rd, 7th days of treatment with the score assessment of symptoms (cough, stuffy nose, auscultation data) and an indication of adverse events (if any).Results. Improvement of condition was noted in most patients by the 3rd day of therapy (mean score 1.88 ± 0.3), temperature normalized in all patients, manifestations of rhinitis decreased. By the 5th day of treatment, the intensity of cough did not exceed 1 point in all patients (0.7 ± 0.14 points). According to the patient’s diary data, by the 7th day of treatment 74% of the children had no cough. On the 7th day of treatment, some children had a rare residual cough (0.36 ± 0.06 points), minor rhinitis (0.16 ± 0.1 points). No rales were heard in the lungs in all patients, rigid breathing was heard in 11 patients (mean score 0.22 ± 0.05).Conclusions. The conducted study demonstrated that 3% hypertonic saline with hyaluronic acid is an effective drug in the treatment of cough in acute bronchitis in children.